Association of hemoglobin and survival in peritoneal dialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 8, 2011, Pages 1973-1981

  Molnar, Miklos Z ^a,c   Mehrotra, Rajnish ^b,d   Duong, Uyen ^a   Kovesdy, Csaba P ^e,f   Kalantar Zadeh, Kamyar ^a,b,d,g  

^a Harold Simmons Center for Chronic Disease Research and Epidemiology   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; RACE DIFFERENCE; SEX DIFFERENCE; SURVIVAL RATE;

ADULT; AFRICAN AMERICANS; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; DOWN-REGULATION; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 80051573899     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01050211     Document Type: Article

References (20)

1. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001
2. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE: Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 69: 560-564, 2006
3. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
4. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
5. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
6. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF: Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153: 23-33, 2010
7. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
8. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N: Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl (87): S6-S11, 2003
9. Li S, Foley RN, Collins AJ: Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 65: 1864-1869, 2004
10. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ: Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 15: 174-179, 2004
11. Centers for Medicare and Medicaid Services: 2008 Annual Report, End Stage Renal Disease Clinical Performance Measures Project, in Baltimore, Maryland, Department of Health and Human Services, Center for Medicare and Medicaid Services, Office of Clinical Standards and Quality, December 2008
12. Sedor JR, Watnick S, Patel UD, Cheung A, Harmon W, Himmelfarb J, Hostetter TH, Inrig JK, Mehrotra R, Robinson E, Smedberg PC, Shaffer RN: ASN End-Stage Renal Disease Task Force: Perspective on prospective payments for renal dialysis facilities. J Am Soc Nephrol 21: 1235-1237, 2010
13. Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG: Anemia management and association of race with mortality and hospitalization in a large not-forprofit dialysis organization. Am J Kidney Dis 54: 498-510, 2009
14. Duong U, Mehrotra R, Molnar MZ, Noori N, Kovesdy CP, Nissenson AR, Kalantar-Zadeh K: Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 6: 1041-1048, 2011
15. Mehrotra R, Duong U, Jiwakanon S, Kovesdy CP, Moran J, Kopple JD, Kalantar-Zadeh K: Serum albumin as a predictor of mortality in peritoneal dialysis: Comparisons with hemodialysis. Am J Kidney Dis 2011, in press [Epub ahead of print]
16. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 11: 520-529, 2000
17. Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med 8: 551-561, 1989
18. Duke M, Abelmann WH: The hemodynamic response to chronic anemia. Circulation 39: 503-515, 1969
19. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 53: 823-834, 2009
20. Kilpatrick RD, Block G, Horwich T, Derose SF: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18: 293-303, 2007